RemeGen (HKG:9995, SHA:688331) reported a net loss attributable to shareholders of 291.0 million yuan for the quarter ended Sept. 30, according to a Tuesday filing with the Hong Kong bourse.
The loss per share for the quarter was 0.54 yuan.
Revenue was 467.1 million yuan, a 34.60% increase from the prior-year quarter.
Hong Kong shares of the biopharmaceutical company gained 3% in morning trade Wednesday, while its Shanghai shares gained nearly 4%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.